Quoin Pharmaceuticals Ltd DRC Cash Flow Conversion Efficiency
Quoin Pharmaceuticals Ltd DRC cash flow conversion efficiency. Based on the latest financial reports, Quoin Pharmaceuticals Ltd DRC (QNRX) has a cash flow conversion efficiency ratio of -0.817x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.21 Million) by net assets ($3.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Quoin Pharmaceuticals Ltd DRC (2015–2025)
Cash flow conversion efficiency of Quoin Pharmaceuticals Ltd DRC from 2015 to 2025. This chart illustrates how Quoin Pharmaceuticals Ltd DRC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Quoin Pharmaceuticals Ltd DRC stock price today for real-time trading data and today's change.
Quoin Pharmaceuticals Ltd DRC Cash Flow Conversion Ratio Explained
Quoin Pharmaceuticals Ltd DRC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Quoin Pharmaceuticals Ltd DRC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quoin Pharmaceuticals Ltd DRC ranked by their cash flow conversion efficiency. Also see Quoin Pharmaceuticals Ltd DRC stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lite Access Technologies Inc
V:LTE
|
1.235x |
|
Radiant Utama Interinsco Tbk
JK:RUIS
|
0.083x |
|
Millennium Silver Corp
V:MSC
|
0.019x |
|
GRAFT POLYMER UK LS -001
F:J4I
|
-0.024x |
|
Dovre Group Plc
HE:DOV1V
|
-0.559x |
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
-0.309x |
|
Coloured Ties Capital Inc
V:TIE
|
-0.031x |
|
SG COMPANY S.P.A.
F:7KZ
|
N/A |
Annual Cash Flow Conversion Efficiency for Quoin Pharmaceuticals Ltd DRC (2015–2025)
The table below shows the annual cash flow conversion efficiency of Quoin Pharmaceuticals Ltd DRC from 2015 to 2025. Review financial agility of Quoin Pharmaceuticals Ltd DRC to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $13.12 Million | $-13.54 Million | -1.032x | -20.91% |
| 2024-12-31 | $9.20 Million | $-7.86 Million | -0.854x | +38.52% |
| 2023-12-31 | $5.66 Million | $-7.86 Million | -1.388x | -21.27% |
| 2022-12-31 | $7.41 Million | $-8.48 Million | -1.145x | +86.85% |
| 2021-12-31 | $657.03K | $-5.72 Million | -8.706x | -4397.13% |
| 2020-12-31 | $-6.61 Million | $-1.34 Million | 0.203x | +115.25% |
| 2019-12-31 | $4.30 Million | $-5.71 Million | -1.329x | +24.69% |
| 2018-12-31 | $3.73 Million | $-6.57 Million | -1.764x | -92.44% |
| 2017-12-31 | $5.43 Million | $-4.98 Million | -0.917x | -80.15% |
| 2016-12-31 | $7.40 Million | $-3.77 Million | -0.509x | +30.78% |
| 2015-12-31 | $2.70 Million | $-1.98 Million | -0.735x | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrom… Read more